Ironwood Pharma to acquire Swiss-based VectivBio in $1 bln deal
22/05/2023 12:05
May 22 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O said on Monday it would acquire Switzerland-based drug developer VectivBio Holding AG VECT.O in a deal valued at about $1 billion, including debt. (Reporting by Raghav Mahobe in Bengaluru; Editing by Janane Venkatraman) ((Raghav.Mahobe@thomsonreuters.com;))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation